3
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Lung Neoplasms
3
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Rectal Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Liver Neoplasms
1
Head and Neck Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
pembrolizumab
30
Nivolumab
12
Carboplatin
6
atezolizumab
5
Trastuzumab
5
aldesleukin
4
Specimen Handling
4
Paclitaxel
4
Magnetic Resonance Spectroscopy
4
Ipilimumab
4
Docetaxel
4
Cyclophosphamide
4
Cisplatin
4
Bevacizumab
4
spartalizumab
3
fludarabine
3
durvalumab
3
Polymerase Chain Reaction
3
Irinotecan
3
Interleukin-2
3
Gene Expression Profiling
3
Blood Specimen Collection
3
Biopsy
3
zimberelimab
2
tisotumab vedotin
2
tislelizumab
2
sargramostim
2
osimertinib
2
enzalutamide
2
cemiplimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uterine Cervical Neoplasms
×
Radionuclide Imaging
×
Thoracic
×
Clear all
NCT06904365
2026-05-18
OvAR-Y
Washington University School of Medicine
Active not recruiting
10 enrolled